Metastatic melanoma: chemotherapy to biochemotherapy

Cancer Control : Journal of the Moffitt Cancer Center
Steven O'DayDouglas S Reintgen

Abstract

Single-agent or combination chemotherapy regimens have not impacted the short median survival of patients with metastatic melanoma, and complete or durable responses are rare. Biologic response modifiers (interferon and interleukin-2) have produced durable remissions in a small cohort of patients, and phase II trials of biochemotherapy suggest more benefit. The authors retrospectively reviewed the status of the current treatments of metastatic melanoma focusing on biochemotherapy. Regimens include both sequential and concurrent approaches for inpatient and outpatient treatment settings. Overall response rates in phase II trials are 40% to 60% with complete responses of 10% to 20% and median survivals in the 11- to 12-month range. Modifications of concurrent biochemotherapy regimens have maintained efficacy and reduced toxicity. Small phase III trials suggest a survival advantage of biochemotherapy (P=.05). Biochemotherapy remains a promising new treatment for metastatic melanoma. A large Intergroup trial E3695 comparing concurrent biochemotherapy to combination chemotherapy alone is powered to answer important survival questions.

References

Nov 1, 1992·Seminars in Surgical Oncology·C M Balch
Feb 20, 1992·International Journal of Cancer. Journal International Du Cancer·E F McClayR E Bellet
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M RichardsP Skosey
Aug 20, 1992·The New England Journal of Medicine·G CocconiP Costa
Aug 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C I FalksonH C Falkson
Feb 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ R Durant
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsR I Fisher
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KhayatR Franks
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Oct 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S LeghaN Papadopoulos
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S S LeghaN Papadopoulos
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U KeilholzM Pritsch
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P B ChapmanJ M Kirkwood
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J O'DayD L Morton
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R MiddletonN Thatcher
May 16, 2000·Cancer Investigation·K HellstrandS Hermodsson
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L E FlahertyW Du
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sanjiv S AgarwalaPeter Naredi

❮ Previous
Next ❯

Citations

Aug 29, 2003·Cancer Gene Therapy·Stacie R BiancoJaime F Modiano
Sep 26, 2003·Cancer·Marko B LensAmna F Husain
Dec 4, 2003·Expert Opinion on Biological Therapy·Marko B Lens
Jan 20, 2018·Scientific Reports·Jingtong PanYuehong Xu
Jul 26, 2007·BMC Musculoskeletal Disorders·Kuo-Yuan HuangRong-Sen Yang
Aug 19, 2006·Journal of Surgical Oncology·Shawn E YoungRichard Essner
Oct 26, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·D NashanA Enk
Dec 17, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Van Anh Trinh
Nov 21, 2012·Melanoma Research·Jannemarie de RidderUNKNOWN Dutch Liver Working Group
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gheath AlatrashRonald M Bukowski
Nov 13, 2004·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Barbara LoewenthalRoger Garcia
May 17, 2013·American Journal of Clinical Dermatology·Marta BatusHoward L Kaufman
Jul 25, 2009·International Journal of Cancer. Journal International Du Cancer·Ritu AnejaHarish C Joshi
Dec 26, 2006·Expert Review of Anticancer Therapy·Henry B Koon, Michael B Atkins
May 27, 2021·Journal of Molecular Modeling·Swarnadeep Biswas, Pradeep Kumar Shukla
Oct 2, 2007·Experimental Cell Research·Natalie N BauerOystein Fodstad
Nov 17, 2009·Clinics in Plastic Surgery·Jonathan Treisman, Nina Garlie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.